Evidence - Esophageal resection

  1. Literature summary

    Multimodal management of esophageal carcinoma

    With around 6,500 new cases each year, esophageal cancer is a somewhat rare malignancy in Germany, although its incidence is increasing. In about 50 - 60% of cases the tumor is squamous cell carcinoma. In recent years, adenocarcinoma, which is predominantly located in the inferior third of the esophagus, has been diagnosed more frequently.

     At the time of diagnosis, only 25% of patients are in an early tumor stages (T1, T2), which is why the 5-year survival rate in Germany is only between 22% and 24% [1]. Evidence-based multimodal management can improve survival from stage cT3 and up and is therefore indicated [2]:

    • T1a: Mucosectomy or endoscopic mucosal resection
    • T1b to T2: Primarily surgical resection as treatment of choice; in T2 with positive lymph node involvement, preoperative multimodal therapy is optional
    • T3 to T4:  Preoperative multimodal therapy + surgical resection regardless of any lymph node involvement

    In resectable squamous cell carcinoma stage T3 and up, preoperative radiochemotherapy represents the standard, while perioperative chemotherapy and radiochemotherapy are considered equivalent options for adenocarcinoma stage T3 and up. Squamous cell carcinoma may also be cured with definitive radiochemotherapy [2].  Radiochemotherapy focuses on the maximum local effect, while perioperative chemotherapy centers on the optimal systemic effect [3, 4, 5, 6, 7].

    Esophageal resection

    Surgical treatment of esophageal carcinoma aims at total removal of the tumor, orally, aborally and circumferentially [2]. Due to early lymphogenic metastasis, local endoscopic ablation is only useful in early forms of both squamous cell carcinoma and adenocarcinoma (T1a), while in stages > T1a resection including lymphadenectomy is indicated.

    The current standard is abdominal and thoracic 2-field lymph node dissection (2-field LND) with resection of the para-esophageal lymph nodes (LN) in the resection area of the thoracic esophagus (including the infracarinal and parabronchial LNs; thoracic compartment) as well as the abdominal paracardial LNs and the LNs along the celiac trunk and its branches (abdominal compartment). Cervical LND may also be necessary in the case of cancer high up in the chest [2]. Sentinel LND after multimodal therapy is uncertain and therefore not recommended [8]. At present there is no definitive statement on the minimum number of nodes in LND.

    In tumors of the middle and distal esophagus, abdominothoracic resection with gastric tube transposition is regarded as standard procedure. If the stomach is not available as a conduit, one alternative would be the colon [2]. A left thoracic approach is possible in the standard procedure, but a more superior right thoracic approach is usually chosen because it provides significantly better exposure of the thoracic LNs, as is also demonstrated in the video (Ivor-Lewis operation [9]). As the level of the esophageal anastomosis increases, anastomotic failure, stricture and dysphagia increase significantly and the quality of life decreases [10]. For this reason, intrathoracic anastomosis is preferred.

    In case of tumors of the distal esophagus (Sievert II carcinomas), there are currently no recommendations regarding access via the Ivor-Lewis procedure or extended transhiatal gastrectomy [2]. However, detailed analyses of the so-called Sievert II carcinomas demonstrated a difference depending on the spread of the superior tumor margin into the esophagus. Kurokawa et al [11] found a higher percentage of patients with mediastinal lymph node recurrence after transhiatal resection, which is why in adenocarcinoma at the gastroesophageal junction Ivor-Lewis esophagectomy with proximal gastric resection is increasingly performed instead of extended transhiatal gastrectomy.

    The German S3 guideline on "Diagnostics and therapy of squamous cell carcinoma and adenocarcinoma of the esophagus" recommends that both esophagectomy and esophageal reconstruction be performed as minimally invasive procedures or combined with an open approach (hybrid technique) [2]. Since the oncological results so far seem comparable to the open approach, minimally invasive resections may today be regarded as primarily desirable for the patient if it is technically feasible and has the surgeons have the appropriate expertise. Prerequisite is an adequate oncological resection with safe intrathoracic anastomosis [12, 13, 14, 15].

  2. Ongoing trials on this topic

    Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)

    Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study

    Status of Superficial Esophageal Cancers Treated by Endoscopy

    Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy for Patients With Squamous Cell Esophageal Cancer: a Multicenter Open-label, Randomized Controlled Trial (RAMIE Trial)

    A Phase II/III Study of Adjuvant Chemoradiotherapy, Radiotherapy After Surgery Versus Surgery Alone in Patients With Stage ⅡB-Ⅲ Esophageal Carcinoma

    Surgery Versus Definitive Chemoradiotherapy for Resectable Cervical Esophageal Squamous Cell Carcinoma: A Prospective Multicenter Open-Label Clinical Trial

    Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients: A Prospective, Multicenter Clinical Trial

    A Randomized, Controlled, Multi-center Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy

    Drainless Robot-assisted Minimally Invasive Esophagectomy

    A Prospective, Multicenter, Randomized, Controlled Study Comparing Surgical Efficacy Between Transhiatal/Transabdominal and Thoracoabdominal Approach for Patients With Siewert II Adenocarcinoma of Esophagogastric Junction

  3. References on this topic

    1. Robert Koch Institut, Zentrum für Krebsregisterdaten (2015) Gesundheitsberichterstattung des Bundes,10. Ausgabe

    2. Porschen R, Fischbach W, Gockel I, Görling U, Grenacher L, Hollerbach  S, Hölscher A , Körber J, Messmann H, Meyer HJ, Miehlke S, Möhler M, Nöthlings U, Pech U, Schmidberger H , Schmidt M, Stahl M, Stuschke M, Thuss-Patience P, Trojan J, Vanhoefer U, Weimann A, Wenz F, Wullstein C (2015) S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 – September 2015, AWMF Registernummer:021/023OL). Z Gastroenterol 53(11):1288–1347.

    3. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van BergeHenegouwenMI,Wijnhoven BP et al (2012) Preoperative chemoradiotherapy for esophagealor junctional cancer. N Engl J Med 366(22):2074–2084

    4. Shapiro J, vanLanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven B Petal (2015) Neoadjuvantchemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS): long-termresults of a randomised controlled trial. Lancet Oncol 16(9):1090–1098

    5. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE et al (2013) Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev

    6. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, BarbourAetal(2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophagealcarcinoma: anupdated meta-analysis. Lancet Oncol 12(7):681–692

    7. Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D et al(2015) TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 15:532

    8. Boone J, Hobbelink MG, Schipper ME, Vleggaar FP,Borel Rinkes IH, de Haas RJ et al(2016) Sentinel node biopsy during thoracolaparoscopic esophagectomy for advanced esophageal cancer. World J Surg Oncol 14:117

    9. Ma Q, Liu W, Long H, Rong T, Zhang L, Lin Y et al (2015) Right versus left transthoracic approach for lymphnode-negative esophageal squamous cell carcinoma. JCardiothoracSurg10:123

    10. Allum WH, Bonavina L, Cassivi SD, Cuesta MA, Dong ZM, Felix VN et al (2014) Surgical treatments for esophagealcancers. AnnNYAcad Sci1325:242–268

    11. Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M et al (2015) Mediastinal lymphnode metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery 157(3):551–555

    12. Luketich JD, Pennathur A, Awais O, Levy RM, Keeley S, Shende Metal (2012) Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg 256(1):95–103

    13. Dantoc MM, Cox MR, Eslick GD (2012) Does minimally invasive esophagectomy (MIE) provide for comparable oncologic outcomes to open techniques? A systematic review. J Gastrointest Surg 16(3):486–494

    14. Luketich JD, Pennathur A, Franchetti Y, Catalano PJ, Swanson S, Sugarbaker  DJ et al(2015) Minimally invasive esophagectomy: results of a prospective phase II multicenter trial-the eastern cooperative oncology group(E2202) study. Ann Surg 261(4):702–707

    15. Palazzo F, Rosato EL, Chaudhary A, Evans NR 3rd, Sendecki JA, Keith S et al (2015) Minimally invasive esophagectomy provides significant survival advantage compared with open or hybrid esophagectomy for patients with cancers of the esophagus and gastroesophageal junction. J Am CollSurg220 (4):672–679

Reviews

A-Lai GH, Xu ZJ, Yao P, Zhong X, Wang YC, Lin YD. Prognostic value of node skip metastasis on esoph

Activate now and continue learning straight away.

Single Access

Activation of this course for 3 days.

€7.99 inclusive VAT

Most popular offer

webop - Savings Flex

Combine our learning modules flexibly and save up to 50%.

from €3.29 / module

€39.50 / yearly payment

price overview

general and visceral surgery

Unlock all courses in this module.

€12.42 / month

€149.00 / yearly payment

  • literature search

    Literature search on the pages of pubmed.